Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Phase 2

Terminated

Conditions: Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Transitional Cell Carcinoma of the Bladder

Interventions: Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2006-08-15

Last Posted Date: 2015-02-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00363883

Locations: 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: docetaxel
Drug: bortezomib
Other: laboratory biomarker analysis
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: pharmacological study

First Posted Date: 2006-08-15

Last Posted Date: 2017-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 81

Registration Number: NCT00362882

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD

Not Applicable

Completed

Conditions: Renal Osteodystrophy

First Posted Date: 2006-08-15

Last Posted Date: 2015-04-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT00364234

Locations: 🇺🇸
Childen's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Childhood Burkitt Lymphoma
Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma
Childhood Low-grade Cerebral Astrocytoma

Interventions: Drug: ispinesib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-08-15

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00363272

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

Phase 2

Terminated

Conditions: Large Granular Lymphocytic Leukemia
LGL Leukemia

Interventions: Drug: Cyclosporine
Genetic: Gene expression analysis
Genetic: Microarray analysis
Other: Laboratory biomarker analysis

First Posted Date: 2006-08-15

Last Posted Date: 2015-07-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT00363779

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Glycemic Relapse Prevention: Maintenance Dose Assessment

Phase 4

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2006-08-09

Last Posted Date: 2010-02-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 165

Registration Number: NCT00362193

Substrate Cycling in Energy Metabolism

Phase 2

Completed

Conditions: Burns
Insulin Resistance

First Posted Date: 2006-08-09

Last Posted Date: 2010-02-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 40

Registration Number: NCT00361751

Locations: 🇺🇸
Shriners Hospital for CHildren, Galveston, Texas, United States

Diabetes Control and Complications Trial (DCCT)

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

First Posted Date: 2006-08-07

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1441

Registration Number: NCT00360815

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
International Diabetes Center, Minneapolis, Minnesota, United States
🇺🇸
DCCT Central Nutrition Coding Unit, Minneapolis, Minnesota, United States

and more 35 locations

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

Phase 2

Terminated

Conditions: Stage III Chronic Lymphocytic Leukemia
T-cell Large Granular Lymphocyte Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2006-08-07

Last Posted Date: 2017-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00360776

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

Efficacy of Increasing Physical Activity to Reduce Children's Visceral Fat

Phase 1

Completed

Conditions: Obesity

Interventions: Behavioral: Pediatric Obesity Intervention (STANDARD)
Behavioral: Pediatric Obesity Intervention + High Activity (ADDED)

First Posted Date: 2006-08-03

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 29

Registration Number: NCT00359957

Locations: 🇺🇸
Children's Hospital and Regional Medical Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy